Abcellera Biologics Inc (ABCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 161,788 | 168,573 | 153,464 | 93,516 | 114,898 |
| Depreciation Amortization | 11,014 | 4,973 | 17,250 | 10,492 | 8,181 |
| Income taxes - deferred | N/A | N/A | -2,018 | N/A | N/A |
| Accounts receivable | 21,086 | -176,665 | 59,864 | 159,998 | 144,429 |
| Accounts payable and accrued liabilities | -1,882 | 751 | -3,237 | -313 | -3,640 |
| Other Working Capital | 176,326 | -85,026 | 41,672 | 138,059 | 129,912 |
| Other Operating Activity | 4,902 | 187,613 | -22,411 | -140,456 | -126,552 |
| Operating Cash Flow | $373,234 | $100,219 | $244,584 | $261,296 | $267,228 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 11,502 | -2,815 | -247,102 | -235,787 | N/A |
| PPE Investments | -45,817 | -14,495 | -58,452 | -49,022 | -40,448 |
| Net Acquisitions | N/A | N/A | -11,457 | -11,457 | N/A |
| Purchase Of Investment | -27,351 | -11,657 | -47,857 | -44,639 | -25,544 |
| Other Investing Activity | 8,098 | 2,596 | 32,621 | 9,807 | 4,520 |
| Investing Cash Flow | $-53,568 | $-26,371 | $-332,247 | $-331,098 | $-61,472 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 2,175 | 1,941 | 5,487 | 3,653 | N/A |
| Debt Repayment | N/A | N/A | N/A | -4,373 | -4,373 |
| Common Stock Issued | N/A | N/A | N/A | N/A | 2,755 |
| Other Financing Activity | -4,133 | -5,072 | -9,373 | -5,000 | -5,000 |
| Financing Cash Flow | $-1,958 | $-3,131 | $-3,886 | $-5,720 | $-6,618 |
| Exchange Rate Effect | -1,411 | -204 | -1,425 | -900 | -683 |
| Beginning Cash Position | 501,142 | 501,142 | 594,116 | 594,116 | 594,116 |
| End Cash Position | 817,439 | 571,655 | 501,142 | 517,694 | 792,571 |
| Net Cash Flow | $316,297 | $70,513 | $-92,974 | $-76,422 | $198,455 |
| Free Cash Flow | |||||
| Operating Cash Flow | 373,234 | 100,219 | 244,584 | 261,296 | 267,228 |
| Capital Expenditure | -45,817 | -14,495 | -58,452 | -49,022 | -40,448 |
| Free Cash Flow | 327,417 | 85,724 | 186,132 | 212,274 | 226,780 |